Bristol-Myers Squibb Co.

NYSE:BMY  
61.30
+0.07 (+0.11%)
4:00:00 PM EDT: $61.28 -0.02 (-0.03%)
Products

U.S. FDA Accepts For Priority Review Bristol Myers Squibb’s Application For Orencia To Prevent Acute Graft Versus Host Disease (Agvhd)

Published: 08/23/2021 12:47 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (agvhd).
Bristol-myers Squibb Co - FDA Assigned an Action Date of December 23, 2021 for Orencia.